Bolt Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer. The company is headquartered in Redwood City, California and currently employs 94 full-time employees. The company went IPO on 2021-02-05. The firm is engaged in the development of immunotherapies for the treatment of cancer. Its proprietary Boltbody ISAC (immune-stimulating antibody conjugate) platform technology combines tumor-targeting antibodies with immune-stimulating linker payloads to create productive anti-tumor immune responses. This approach creates products that work with a patient’s own immune system, resulting in anti-cancer efficacy with tolerability. Its first Boltbody ISAC is its BDC-1001 program, targeting a tumor antigen, HER2. BDC-1001 completed a dose-escalation trial and is advancing into multiple Phase II clinical trials. BDC-3042, its Dectin-2 agonist antibody program, is being developed to repolarize critical cells in the tumor microenvironment known as tumor-associated macrophages (TAMs) by targeting cell-surface receptors.